Milky Way Subsystems from Globular Clusters Kinematics Using Gaia DR2 and HST Data

We employ Gaia DR2 proper motions for 151 Milky Way globular clusters from Vasiliev (2019) in tandem with distances and line-of-sight velocities to derive their kinematical properties. To assign clusters to the Milky Way thick disk, bulge, and halo we follow the approach of Posti et al. (2018) who distinguished among different Galactic stellar components using stars's orbits. In particular, we use the ratio $L_{z}/e$, the $Z$ projection of the angular momentum to the eccentricity, as population tracer, which we complement with chemical abundances extracted from the literature and Monte-Carlo simulations. We find that 20 globular clusters belong to the bar/bulge of the Milky Way, 35 exhibit disk properties, and 96 are members of the halo. Moreover, we find that halo globular clusters have close to zero rotational velocity with average value $$ =1$\pm$ 4 km s$^{-1}$. On the other hand, the sample of clusters that belong to the thick disk possesses a significant rotation with average rotational velocity 179 $\pm$ 6 km s$^{-1}$. The twenty globular clusters orbiting within the bar/bulge region of the Milky Way galaxy have average rotational velocity of 49 $\pm$ 11 km s$^{-1}$.Comment: 25 pages, 10 Figures, 5 Tables. Accepted to Astrophysical Journa

Literature review and clinical observation of acquired idiopathic hemophilia with a new missense mutation in the factor VIII gene (His2026Arg)

The article provides review of possible mechanisms of inhibitor coagulopathies, in particular of acquired hemophilia A. This pathology is an extremely rare disease occurring in 1-2 cases in 1 million per year. In the present study we provide data for two clinical cases of hemophilia A in women. These cases had different development mechanisms, although both women have a newly discovered missense mutation His2026Arg in the VIII factor gene. The matter of main interest is the description of the disease development in the patient with an acquired idiopathic hemophilia A with a possible disease occurrence due to an asymmetric X-chromosome inactivation (lyonization). In this particular case lyonization led to the late manifestation of the hemophilia A carrier’s state and development of severe form of the inhibitor-associated acquired hemophilia A. We also discuss therapeutic approaches to these forms of the disease, considering there are no concise protocols for case management due to an extreme rarity of the pathology. Acquainting the clinical personnel working it the different areas of medicine with suchlike inhibitor coagulopathies has a major practical importance

COMPARISON OF THERAPIES BASED ON CARVEDILOL AND METOPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT OR OBESITY. THE FIRST RESULTS OF CAMELLIA TRIAL

Aim. To evaluate antihypertensive and metabolic effects of the therapy based on carvedilol (C) in comparison with metoprolol (M) in hypertensive patients with overweight or obesity.Material and methods. 320 patients were involved in multicenter, randomized open parallel study. One part of the patients received C 12,5 mg BID (Vedicardol, “Sintez”), another part – M 25 mg/day BID. Doubling dose of β-blockers (BB) and switching patients to combined therapy with AML 5-10 mg OD (Amlorus, “Sintez”) and hydrochlorothiazide (HCT) 12,5-25 mg OD was performed if necessary. The study duration was 24 weeks.Results. Significant reduction of systolic and diastolic blood pressure was revealed in both groups, there was no difference between groups (р=0,88 and p=0,61 respectively). Switching patients to combined therapy with AML and HCT was made more often in M group than in C group (p&gt;0,05). Prescription of BB resulted in significant reduction of the heart rate, there was no difference between groups (p=0,61). 96,2% patients of group C and 95,5% of group M reached target levels of BP. Significant reduction of glucose (p&lt;0,01) and uric acid levels were registered in group C as well as tendency to lowering of total cholesterol (TC) and low density lipoprotein cholesterol (LDLC) levels. 34 adverse effects were registered during observation period: 24 in group C and 10 in group M (p&gt;0.05), half of them were not related to BB taking.Conclusion: Controlled antihypertensive therapy, based on С and M, allows reaching target levels of BP in majority of patients with overweight or obesity. Switching to combined therapy was made more seldom in group of С than in M group. Both drugs demonstrated metabolic neutrality, however significant lowering of glucose and uric acid levels and tendency to lowering of TC an LDLC levels was observed only in group С.</p